Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician

Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or rever...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Medicine Insights. Cardiology 2019, Vol.13, p.1179546819866445-1179546819866445
Main Authors: Perez, Irving E, Taveras Alam, Sara, Hernandez, Gabriel A, Sancassani, Rhea
Format: Article
Language:English
Subjects:
Abbreviations
Breast cancer
Cancer therapies
Cardiac arrhythmia
Cardiomyopathy
Cardiovascular disease
Chemotherapy
Coronary vessels
Diabetes
Drug dosages
Epidermal growth factor
Heart
Heart failure
Hypertension
Immunotherapy
Kinases
Lymphoma
Patients
Peptides
Review
Side effects
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.
ISSN:1179-5468
1179-5468
DOI:10.1177/1179546819866445